- Otsuka Holdings Co. Ltd.
- Sihuan Pharmaceutical Holdings Group Ltd.
- ShangPharma Corp.
- Zogenix Inc.
- Zealand Pharma AS
- Regeneron Pharmaceuticals Inc.
- Cadence Pharmaceuticals Inc.
- BioSante Pharmaceuticals Inc.
- Cyclacel Pharmaceuticals Inc.
- Pearl Therapeutics Inc.
- Pfizer Inc.
- King Pharmaceuticals Inc.
- Laboratorio Teuto Brasileiro SA
- Royal DSM NV
- Martek Biosciences Corp.
- Amerifit Brands Inc.
- Reckitt Benckiser Group PLC
- Paras Pharmaceuticals Ltd.
- Abbott Laboratories Inc.
- Piramal Enterprises Ltd.
- BMP Sunstone Corp.
- GlaxoSmithKline PLC
- Takeda Pharmaceuticals International GmbH
- Guangdong Techpool Bio-Pharma Co. Ltd.
- University of California
- University of California, San Francisco
- Stromedix Inc.
- Cephalon Inc.
- Mesoblast Ltd.
- Genzyme Corp.
- Osiris Therapeutics Inc.
- Biocon Ltd.
- Nektar Therapeutics
- Akorn-Strides LLC
- Akorn Inc.
- Strides Shasun Ltd.
- Adimab LLC
- Human Genome Sciences Inc.
- Genentech Inc.
- Ablexis LLC
- MacroGenics Inc.
- Boehringer Ingelheim International GmbH
- AstraZeneca PLC
- Merck & Co. Inc.
- Sanofi-Aventis US LLC
- Merck KGaA
- Merck Serono SA
- Avila Therapeutics Inc.
- Otsuka nets Yen198.6bn via its IPO on the Tokyo Stock Exchange
- Sihuan Pharmaceutical grosses HK$5.75bn via its IPO
- Zogenix nets $53.4mm in initial public offering
- Zealand Pharma nets DKK321mm through its IPO
- Zealand Pharma licenses Aventis rights to diabetes compound
- Regeneron nets $174.7mm via follow-on offering
- FOPO nets $94mm for Cadence Pharmaceuticals
- BioSante nets $16.9mm through registered direct offering
- Cyclacel brings in $14.1mm so far through private placement
- Series C brings in $69mm for Pearl Therapeutics
- Pfizer to acquire King for $3.56bn, gains pain portfolio
- Pfizer buys 40% of Laboratorio Teuto Brasileiro SA for $240mm
- DSM buys Martek Biosciences for $1.1bn in cash
- Martek acquires Amerifit Brands for $200mm in cash
- Reckitt Benckiser buys Paras Pharmaceuticals for $726mm
- Abbott to pay $3.72bn for Piramal's branded generics business
- Sanofi will pay $511mm to take over BMP Sunstone
- Glaxo spends $70mm for Chinese urology specialist MeiRui
- Nycomed takes 51.34% ownership in China's Techpool
- Pfizer, UCSF ally to develop new medicines faster
- Stromedix licenses a preclinical antibody from UCSF
- Mesoblast partners stem cell drugs exclusively with Cephalon
- Genzyme gets rights to Osiris's Prochymal and Chondrogen; deal terminated
- Pfizer teams up with Biocon for diabetes biosimilars; deal ends
- Inhale, Pfizer end inhaled insulin deal
- Akorn-Strides sells product portfolio to Pfizer
- Pfizer gets 40 generics from Strides Arcolab
- Pfizer to market 38 generic cancer drugs for Strides Arcolab
- HGS options antibodies from Adimab
- Lilly calls on Adimab in antibody discovery alliance; expanded
- Genentech chooses two targets in antibody deal with Adimab
- Five Big Pharmas get nonexclusive rights to Ablexis mouse; added one more partner; and another
- Ablexis LLC closes its $12mm Series A round
- MacroGenics to use DART platform against two Pfizer targets
- BI signs ten-target DART alliance with MacroGenics
- AstraZeneca, Merck investigate combination cancer therapy
- Sanofi, Merck Serono combine targeted cancer therapies
- Avila to use its Avilomics platform in Sanofi deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.